Effects of soybean milk, chitosan, and anti-Streptococcus mutans IgY in malnourished rats' dental biofilm and the IgY persistency in saliva

Effects of Chicken Egg Powder, Bovine Colostrum, and Combination Therapy for the Treatment of Gastrointestinal Disorders

Natural-based products are of interest to the pharmaceutical industry as potential sources of novel medicinal compounds. They are also used by consumers/patients as standalone therapies or as an adjunct to Western medicines. Two natural-based products of interest are chicken egg and bovine colostrum (the milk produced in the first few days following calving). Both products are rich in immunoglobulins, antimicrobial peptides, growth factors, and macro- and micro-nutrients. In vitro, in vivo, and a limited number of clinical studies suggest therapeutic benefits of both components given alone and together. Combination therapy is of particular interest, as preclinical studies suggest synergistic effects on growth, repair, and gut protection, including microbiome-induced damage. This article describes the main constituents of egg and bovine colostrum, studies of their use alone and together for a wide range of conditions, highlights areas requiring further research, and describes novel indications such as GLP-1-associated gut symptoms. While well placed in the food supplement arena, additional high-quality clinical trials are required to establish their benefits in clinical practice.

Efficacy of Immunoglobulin Y Chewable Tablets on Streptococcus mutans Count in Patients Undergoing Orthodontic Treatment

Aim

The aim of the study was to determine the efficacy of commercially available immunoglobulin Y (IgY) chewable tablets on Streptococcus mutans (S. mutans) count in patients undergoing orthodontic treatment.

Materials and methods

Participants aged between 12 and 19 years who had fixed, nonextraction orthodontic treatment with no carious lesion were included in the study and advised to take IgY chewable tablet for 15 days (one course) and saliva samples were collected from the patients on day 61, 91, and 121 days from the placement of fixed appliance, to assess its ability in reduction of S. mutans count. The collected samples were processed, and S. mutans levels were estimated. The results were tabulated and subjected to statistical analysis using Statistical Package for the Social Sciences (SPSS) version 20, and the repeated measures test was used to compare different groups.

Results

Immunoglobulin Y (IgY) chewable tablet was found to be significantly effective in decreasing S. mutans counts in patients undergoing orthodontic treatment during the study period.

Conclusion

Oral passive immunotherapy via egg yolk antibody IgY effectively decreased the S. mutans level, which was found to increase during orthodontic fixed appliance treatment.

Clinical significance

The IgY chewable tablets can be used as an adjuvant to reduce S. mutans counts and provide basic oral hygiene measures.

How to cite this article

Muthukumaran M, Jayaprakash J, Arangannal P, et al. Efficacy of Immunoglobulin Y Chewable Tablets on Streptococcus mutans Count in Patients Undergoing Orthodontic Treatment. Int J Clin Pediatr Dent 2024;17(3):265-269.

Immunoglobulin A response to SARS-CoV-2-N-protein potentially persists in oral fluids of patients with periodontitis six months after mRNA vaccine administration

Few studies have investigated the mucosal immune response after BNT162b2-booster vaccination in individuals with periodontitis. In this study, we evaluated the persistence of IgA anti-SARS-CoV-2-N-protein in saliva and gingival crevicular fluid (GCF) of patients with periodontitis for at least six months post BNT162b2 vaccine booster. We included patients with moderate (n = 7) and severe (n = 7) periodontitis and participants without periodontitis (n = 7) as controls. The Bradford method measured the protein concentrations in the samples, and an enzyme-linked immunosorbent assay of the SARS-CoV-2 N protein was performed to analyze the targeted IgA level. For the tested SARS-CoV-2 antigen (N-protein), IgA levels in saliva and GCF showed a strong and significant correlation. Therefore, in patients with moderate or severe periodontitis, saliva and GCF can provide information regarding the IgA response against SARS-CoV-2-N-protein. The neutralizing activity of IgA against SARS-CoV-2 was not investigated in this study, necessitating further research.

IgYs: on her majesty's secret service

There has been an increasing interest in using Immunoglobulin Y (IgY) antibodies as an alternative to "classical" antimicrobials. Unlike traditional antibiotics, they can be utilized on a continual basis without leading to the development of resistance. The veterinary IgY antibody market is growing because of the demand for minimal antibiotic use in animal production. IgY antibodies are not as strong as antibiotics for treating infections, but they work well as preventative agents and are natural, nontoxic, and easy to produce. They can be administered orally and are well tolerated, even by young animals. Unlike antibiotics, oral IgY supplements support the microbiome that plays a vital role in maintaining overall health, including immune system function. IgY formulations can be delivered as egg yolk powder and do not require extensive purification. Lipids in IgY supplements improve antibody stability in the digestive tract. Given this, using IgY antibodies as an alternative to antimicrobials has garnered interest. In this review, we will examine their antibacterial potential.

A Comparative Evaluation of Xylitol Chewing Gum and a Combination of IgY + Xylitol Chewable Tablet on Salivary Streptococcus mutans Count in Children: A Double-blind Randomized Controlled Trial

Aim

The study was designed for evaluation and comparison of the efficacy of Xylitol chewing gum and a combination of IgY + Xylitol chewable tablet (Nodecay ^TM) against the “salivary Streptococcus mutans ” count in children.

Materials and methods

About 120 children belonging to 6-12 years age-group were enrolled into this “double-blind randomized control clinical trial” according to the selection criteria. They were randomly assigned to three groups of 40 each: Group I-Xylitol chewing gum, Group II-IgY + Xylitol Chewable tablet (Nodecay ^TM), and Group III-Control. Children in all the groups had to chew the gum/tablet twice daily for 5 minutes during the 15-day period. The salivary samples at baseline, 15 days, 1, 2, and 3 months were inoculated on mitis salivarius bacitracin agar with potassium tellurite medium and the number of colony-forming units (CFUs) of Streptococcus mutans were determined. The data obtained was subjected to statistical analysis.

Result

There was a “significant” difference in the number of “S. mutans CFUs” amongst the three groups at 15 days, 1st month, 2nd month, 3rd month with highest levels of S. mutans CFUs in Group III-Control and least in Group II-IgY + Xylitol (Nodecay^TM).

Conclusion

The combination of IgY + Xylitol (Nodecay^TM) when administered for 15 days had significant efficacy against “S. mutans” when compared to Xylitol and control group.

Clinical significance

Passive immunization with immunoglobulin Y is known not only to decrease the S. mutans count but also confers extended immunity by preventing recolonization of the tooth surface by persistence of the antibodies in saliva.

How to cite this article

Jain RL, Tandon S, Rai TS, et al. A Comparative Evaluation of Xylitol Chewing Gum and a Combination of IgY + Xylitol Chewable Tablet on Salivary Streptococcus mutans Count in Children: A Double-blind Randomized Controlled Trial. Int J Clin Pediatr Dent 2022;15(S-2):S212-S220.

Chitosan gel prevents the growth of Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola in mini-implant during orthodontic treatment

Aims

We evaluated the effect of chitosan gel on total oral bacteria, Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola, during orthodontic treatment with mini-implants.

Material and methods

Thirty subjects with 52 orthodontic mini-implants were divided into three groups: one group was treated with chitosan gel, the other group with chlorhexidine gel, and the control group with placebo. The plaque of the orthodontic peri-mini-implant area was collected before and after gel treatment. The total oral bacteria and red-complex bacteria of P. pingivalis, T. forsythia, and T. denticola were determined with reverse transcription-quantitative PCR.

Results

Thirty-four orthodontic mini-implants (65.38%) appeared as healthy and showed no clinical signs of inflammation. The total number of bacteria was reduced after chitosan gel application. The highest decrease in the proportion of P. gingivalis was observed in the chlorhexidine gel application group, which showed a value of 70.86%, whereas the chitosan gel application showed a reduction of only 26.59%, and the control gel application showed the lowest reduction effect of only 2.55%. The difference in the reduction between gel application groups was significant (P < 0.05) for T. denticola and T. forsythia.

Conclusion

The gel containing chitosan reduced the levels of total oral bacteria and red-complex bacteria.

Evaluation of IL-1α and IL-1β, COX-2, and iNOS mRNA Expression in Orthodontic Patients Given Chitosan Mouthwash During Treatment with Miniscrew

Objective:

Chitosan is a biomaterial with antibacterial properties that may benefit from maintaining peri-miniscrew hygiene and preventing inflammation. This study aimed to evaluate the expression of inflammatory-related molecules from the gingival crevicular fluid (GCF) after treatment of 1% chitosan when compared with 0.2% chlorhexidine mouthwash of patients with orthodontic miniscrew.

Materials and Methods:

A total of 30 subjects were divided into three groups: the first group received mouthwash containing 1% chitosan, the second group 0.2% chlorhexidine digluconate, and the control group received aquadest. The GCF was collected before and after 4 days of rinsing, and relative expressions of IL-1α and IL-1β, cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS) were evaluated by real-time qPCR.

Results:

The expression of IL-1α was the highest in chitosan-treated patients when compared with that of IL-1β in between-groups. Patients receiving chlorhexidine have the highest expression of COX-2 and iNOS when compared with the chitosan and control groups, respectively.

Conclusion:

A mouthwash containing 1% of chitosan could suppress the expression of inflammatory mediators IL-1β, COX-2, and iNOS.

Immunoglobulin Y for Potential Diagnostic and Therapeutic Applications in Infectious Diseases

Antiviral, antibacterial, and antiparasitic drugs and vaccines are essential to maintaining the health of humans and animals. Yet, their production can be slow and expensive, and efficacy lost once pathogens mount resistance. Chicken immunoglobulin Y (IgY) is a highly conserved homolog of human immunoglobulin G (IgG) that has shown benefits and a favorable safety profile, primarily in animal models of human infectious diseases. IgY is fast-acting, easy to produce, and low cost. IgY antibodies can readily be generated in large quantities with minimal environmental harm or infrastructure investment by using egg-laying hens. We summarize a variety of IgY uses, focusing on their potential for the detection, prevention, and treatment of human and animal infections.

The effect of coating chitosan on Porphyromonas gingivalis biofilm formation in the surface of orthodontic mini-implant

Infection is the main problem for the failure of orthodontic mini-implant. Modern prevention of infection is now focused on local antibacterial coatings on implant devices. Chitosan is biocompatible and has antibacterial properties. Azithromycin is a synthetic antibiotic with immunomodulatory properties in which it has an advantage over the rest of antibiotics. This study aimed to evaluate the effect coating chitosan on the orthodontic mini-implant in Porphyromonas gingivalis biofilm formation. This is an experimental study using 25 orthodontic mini-implants. Five samples were coated with chitosan, 5 samples were coated with chitosan-azithromycin, 5 samples were coated with azithromycin, 5 samples were uncoated, and 5 samples were uncoated and were not exposed to P. gingivalis. P. gingivalis biofilms on the surface of the orthodontic mini-implant were observed after 24 h of incubation. P. gingivalis biofilm mass inhibition was highest in the azithromycin-treated group, followed by chitosan + azithromycin and chitosan only. The one-way ANOVA statistic test and post hoc Bonferroni statistic test of P. gingivalis biofilm mass show a significant difference between and within groups of experiments (P < 0.05). The Pearson correlation test with a value of R = +0.88, indicated that the bacterial viability count and the biofilm mass have a strong positive correlation. In conclusion, orthodontic mini-implant coated with chitosan, chitosan with azithromycin, or azithromycin only effectively suppressed P. gingivalis biofilm formation.

S. mutans Serotype c, C. albicans, Oral Hygiene, and Decayed, Missing, and Filled Teeth in Early Childhood Caries

Purpose:

The purpose of this study was to determine the quantity of Streptococcus mutans serotype c and Candida albicans antigens from dental plaque and their relationship with the Oral Hygiene Index Score (OHI-S) and Decayed, Missing, and Filled Teeth (DMFT) in Early Childhood Caries (ECC) and Severe Early Childhood Caries (S-ECC).

Materials and Methods:

This was a cross-sectional study, including 5 ECC and 32 S-ECC subjects. ECC was classified as a DMFT score < 4, and S-ECC was classified as a DMFT score ≥ 4 at 71 months of age. S. mutans serotype c and C. albicans antigens from dental plaque of ECC and S-ECC patients were measured using enzyme-linked immunosorbent assays. The optical density ​​of S. mutans serotype c and C. albicans antigens was determined at 450 nm. Correlations between S. mutans serotype c and C. albicans antigens and OHI-S in ECC and S-ECC were analyzed.

Results:

There were no significant differences in S. mutans serotype c and C. albicans antigens between ECC and S-ECC patients or between patients with moderate and good OHI-S scores. There was a negative correlation between S. mutans serotype c and C. albicans antigens in ECC patients (r = -0,62; p < 0.05).

Conclusion:

The increase in C. albicans suppresses S. mutans serotype c growth in ECC but not in S-ECC. The findings of this study could be used to discover the molecular mechanisms involved in bacterial-fungal relationships and the contribution of new technologies to reduce ECC.

Egg yolk antibodies (IgY) and their applications in human and veterinary health: A review

Egg yolk constitutes a relevant alternative source of antibodies. It presents some advantages over mammalian serum immunoglobulins regarding productivity, animal welfare and specificity. The main immunoglobulin present in avian blood (IgY) is transmitted to their offspring and accumulates in egg yolks, which enables the non-invasive harvesting of high amounts of antibodies. Moreover, due to structural differences and phylogenetic distance, IgY is more suitable for diagnostic purposes than mammalian antibodies, since it does not react with certain components of the human immune system and displays greater avidity for mammalian conserved proteins. IgY has been extensively used in health researches, as both therapeutic and diagnostic tool. This article aims to review its applications in both human and veterinary health.

Antigenic epitopes on the outer membrane protein A of Escherichia coli identified with single-chain variable fragment (scFv) antibodies

Bacterial meningitis is a severe disease that is fatal to one-third of patients. The major cause of meningitis in neonates is Escherichia coli (E. coli) K1. This bacterium synthesizes an outer membrane protein A (OmpA) that is responsible for the adhesion to (and invasion of) endothelial cells. Thus, the OmpA protein represents a potential target for developing diagnostic and therapeutic agents for meningitis. In this study, we expressed recombinant OmpA proteins with various molecular weights in E. coli. The sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed to check the molecular size of OmpA's full length (FL) and truncated proteins. OmpA-FL protein was purified for immunizing chickens to produce immunoglobulin yolk (IgY) antibodies. We applied phage display technology to construct antibody libraries (OmpA-FL scFv-S 1.1 × 10⁷ and OmpA-FL scFv-L 5.01 × 10⁶) to select specific anti-OmpA-FL scFv antibodies; these were characterized by their binding ability to recombinant or endogenous OmpA using ELISA, immunofluorescent staining, and confirmed with immunoblotting. We found 12 monoclonal antibodies that react to OmpA fragments; seven scFvs recognize fragments spanning amino acid (aa) residues 1-346, aa 1-287, aa 1-167, and aa 60-192, while five scFvs recognize fragments spanning aa 1-346 and aa 1-287 only. Two fragments (aa 246-346 and aa 287-346) were not recognized with any of the 12 scFvs. Together, the data suggest three antigenic epitopes (60 aa-160 aa, 161 aa-167 aa, 193 aa-245 aa) recognized by monoclonal antibodies. These scFv antibodies show strong reactivity against OmpA proteins. We believe that antibodies show promising diagnostic agents for E. coli K1 meningitis.